What happened with PRGO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Perrigo supplies products consumers use for everyday health needs, including nonprescription medicines and infant formula. Most revenue comes from the U.S. and Canada, where it develops and manufactures products mainly sold under retailers’ own labels. Retailers buy these alternatives to nationally advertised brands at lower costs, allowing them to offer lower consumer prices while keeping higher margins. Perrigo also sells its own brands, including Opill.
Outside the U.S. and Canada, the business centers on Europe and primarily sells branded products, including Compeed, ellaOne and Solpadeine. Pharmacies, retailers and wholesalers buy these products, with advertising and in-store promotion supporting consumer demand. Store-brand sales provide cash that Perrigo uses to invest in its own brands.
Walmart is a significant customer, and the ten largest customers together account for nearly half of sales. U.S. store-brand sales depend heavily on retailers’ promotions. Perrigo must meet manufacturing and product requirements; regulated U.S. generic medicines must demonstrate equivalence to their branded counterparts, while third-party patents and regulatory exclusivity can delay market entry.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Perrigo’s results hinge on OTC consumption, store-brand share gains and infant-formula demand, with Reckitt Benckiser, Bayer and Opella also important branded rivals to watch.
Haleon competes with Perrigo for consumer spending on oral care, pain relief, respiratory and digestive health, supplements and therapeutic skin care. Its oral-care and digestive-health sales are worth watching alongside Perrigo’s sales in those categories.
Kenvue’s branded pain, allergy, oral-care, skin-care and nicotine-replacement products compete for consumers with Perrigo’s self-care products. Nicorette is a particularly direct comparison with Perrigo’s NiQuitin in products that help people quit smoking.
Prestige Consumer Healthcare Inc. competes with Perrigo for North American purchases of nonprescription healthcare products through mass retailers, drugstores and online channels, selling branded products against Perrigo’s mainly store-brand offering. Its North American OTC healthcare revenue is the closest line to watch, rather than its international business.
Dr. Reddy’s competes with Perrigo to supply retailers with store-brand nonprescription medicines and to sell nicotine-replacement products outside the United States. Watch its Nicotinell-led quit-smoking portfolio against Perrigo’s NiQuitin and private-label products.
Abbott’s nutrition business competes with Perrigo for infant-formula purchases, so formula demand and competing suppliers’ availability matter to both. Watch Abbott’s formula supply news: infant formula drove the decline in Perrigo’s Americas nutrition sales in 2025.
Procter & Gamble’s consumer-health brands compete with Perrigo’s self-care products for shoppers’ retail spending. Watch its healthcare business rather than overall sales, which also include a broad range of everyday-use products.
Walmart buys Perrigo products to sell to shoppers and accounted for 12.9% of Perrigo’s consolidated net sales in 2025, making its purchasing decisions directly important to Perrigo. Watch Walmart’s store-brand strategy, since Perrigo mainly supplies retailers’ own brands in the U.S. and Canada.
Abbott Laboratories earningsABT
Abbott’s report and formula-supply updates will show whether infant-formula demand and availability may also be affecting Perrigo’s nutrition sales.
Set Abbott’s formula sales and supply against Perrigo’s nutrition sales. Abbott sales growth with reliable supply would suggest demand is present and competing product is available, making Perrigo’s ability to win orders more important. Weak Abbott sales or constrained supply would point to softer demand or tighter availability, either of which could limit Perrigo’s formula sales.
PERRIGO COMPANY PLC earningsThis company
Perrigo’s report will show whether sales of its store-brand and own-brand self-care products are stabilizing and whether gross margin—the share of sales left after product costs—is improving.
Read net sales alongside gross margin. Stable sales with a recovering margin would show that demand, pricing or cost savings are offsetting weaker categories and higher costs. Further declines in both would show that volume and cost pressure still outweigh those offsets, leaving Perrigo’s self-care business unsettled.
Prestige Consumer Healthcare Inc. earningsPBH
Prestige Consumer Healthcare’s North American over-the-counter business will show how demand is moving in retail channels where Perrigo mainly supplies store-brand products.
Focus on sales in Prestige’s North American over-the-counter business. Growth would suggest shoppers are still buying in drugstores, mass retail and online, supporting the channels where Perrigo sells store brands. A decline would point to possible category weakness in those channels, but would not by itself establish that Perrigo’s sales are falling.
Walmart Inc. earningsWMT
Walmart’s report will show whether its store-brand business is growing; Walmart was 12.9% of Perrigo’s 2025 sales, and Perrigo mainly supplies retailers’ own brands.
Watch Walmart’s store-brand business alongside its overall purchasing trends. Growth in store brands with steady purchasing would suggest this sales channel remains supportive; weaker store brands or reduced purchasing could put pressure on Perrigo’s orders from this major customer. Walmart’s overall results alone cannot establish how Perrigo’s sales changed.
